NewsMV
A Nasdaq deficiency letter landed at Oncolytics Biotech Inc. on July 20, 2026, triggering a formal compliance clock for shares of the San Diego-based biotech.
The Nasdaq Listing Qualifications Staff notified the company, which trades under the ticker ONCY on the Nasdaq Capital Market, that its common stock had closed below $1.00 per share for 30 consecutive business days, placing it outside the Minimum Bid Price Requirement defined in Nasdaq Listing Rule 5550(a)(2).
The company now has until January 19, 2027 to return to compliance or face a delisting proceeding. The listing stays active for now The deficiency letter does not immediately remove ONCY from the Nasdaq Capital Market.
Shares continue to trade under the same symbol while the company works through the 180-calendar-day window that Nasdaq Listing Rule 5810(c)(3)(A) grants.
Keep reading